Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today)

Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today)

Ablynx NV signed its third headline-grabbing deal in 10 months and fifth significant alliance overall, a potential €1.3 billion collaboration that likely will be the last of its kind as the company plans to further assert the strong position of its Nanobody platform going forward. (BioWorld Today)

Ablynx NV signed its third headline-grabbing deal in 10 months and fifth significant alliance overall, a potential €1.3 billion collaboration that likely will be the last of its kind as the company plans to further assert the strong position of its Nanobody platform going forward. (BioWorld Today)

NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today)

NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today)